6 best EDC platforms for vaccine and infectious disease trials in 2026

When a vaccine or infectious disease protocol needs twenty new sites live within weeks, not months, your electronic data capture (EDC) system becomes the constraint or the accelerant. Viedoc's EDC software supports rapid multi-site builds, integrated safety and reactogenicity data flows, and audit-ready compliance across the jurisdictions these trials typically span. This comparison reviews six EDC platforms against the criteria that matter most here: build speed under scale-up pressure, adverse event and diary data integration, randomization integrity, and multi-country compliance depth.

You're likely running a multi-country, multi-arm trial where sites launch on a rolling basis, safety signals need to surface within hours rather than days, and every protocol amendment has to be implemented without disrupting sites already enrolling. Blinding integrity matters as much as data quality, since most vaccine efficacy designs are randomized and placebo-controlled, and an unblinding error carries real consequences for trial validity. Your evaluation committee wants to know whether a platform holds up under genuine operational pressure, not just in a sales demo.

Enterprise EDC platforms built for lengthy Phase III oncology programs often assume slow, sequential site activation, which does not match how vaccine and infectious disease trials actually scale during an active enrollment window. Medidata's roughly 90-day build cycle, for example, can outlast the recruitment window a fast-moving infectious disease trial is trying to hit. The platforms reviewed below need to support rapid site onboarding, integrated diary and safety capture, and dependable randomization without requiring a dedicated programming team for every mid-study change.

Best EDC solutions for vaccine and infectious disease trials: quick comparison

These six eClinical platforms represent the most evaluated options for vaccine and infectious disease trials, reviewed across build speed, safety data integration, randomization integrity, and compliance depth.

1. Viedoc

Viedoc's EDC software has powered more than 8,000 global studies, including work for CROs whose footprint spans oncology, vaccines, and infectious disease. Every study built on the platform has passed FDA inspection, a record that matters under the scrutiny placebo-controlled vaccine trials face. Study builds typically go live in as few as 8 weeks, and self-service teams can launch simpler databases in as little as one day.

For placebo-controlled designs, RTSM software handles randomization and kit allocation directly inside the EDC, so unblinding stays a controlled, auditable action. Built-in ePRO capture lets participants log symptoms and reactogenicity events from their own devices, syncing straight into the study database. Viedoc's no-code Designer lets data managers configure and amend studies without a vendor-side programmer, so changes during an outbreak response do not wait on a change-control queue.

Viedoc EDC is certified to ISO 27001 and SOC 2, and supports FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA across the more than 75 countries where studies run today. The platform is available in more than 40 languages, and support runs 24/7 with direct escalation rather than a ticket queue.

Khadija B., on the Enterprise tier, put it plainly in a G2 review. "Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate."

• Study scale: 8,000-plus global studies, with a 100% FDA inspection pass rate
• Build speed: As few as 8 weeks, with self-service builds live in one day
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA; ISO 27001 and SOC 2 certified
• Language and country reach: 40-plus languages across 75-plus countries
• Support: 24/7 support with direct escalation, not a ticket queue
• No-code configuration: Viedoc Designer enables in-house study builds and amendments without a vendor-side programmer

2. Medidata

Medidata offers Rave EDC, an enterprise electronic data capture platform built to capture, clean, and manage trial data so sites, study teams, and regulators can trust the results as protocols change. The platform includes AI-assisted configuration tools that automate repetitive study-build tasks, along with Rave Companion, which transfers data directly from electronic health records into EDC forms to reduce manual site entry. Protocol amendments and mid-study changes can be deployed without downtime, connecting thousands of patients to updated forms within hours rather than months. Rave EDC also connects to the broader Medidata Platform, bringing eConsent, eCOA, and RTSM data into the same database rather than a separate system. Independent sponsor evaluations have named Rave the most preferred EDC in recent industry benchmarking, and the platform is positioned for studies of any phase and therapeutic area, including large-scale, multi-site infectious disease programs run by major pharmaceutical sponsors.

3. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-native electronic data capture module built on the broader Veeva Clinical Platform. The system supports point-and-click study builds without custom programming, and design changes to active studies can be made without migrations or downtime for enrolling sites. Vault EDC includes native DICOM image review alongside standard case report form data, reducing the reconciliation work between imaging and clinical datasets that many trials otherwise require. As part of the wider Veeva Clinical Platform, data flows bidirectionally between Vault EDC and Veeva CDB, RTSM, CTMS, and eTMF, so a single record underpins every connected application. Veeva reports that companies using Vault EDC have reduced data management effort and accelerated execution timelines against legacy systems. The platform serves both large biopharmaceutical companies and emerging biotechs running trials of any phase and complexity.

4. Castor EDC

Castor EDC is an API-driven electronic data capture platform that integrates data from electronic health records, ePRO/eCOA, lab systems, and wearables into a single clinical trial data environment. The platform supports low-complexity study deployment in as little as 3–4 weeks, and Castor states its build times rank among the shortest of the EDC vendors it tracks. Castor's own site notes that the platform supported the WHO Solidarity trial, an infectious disease study that enrolled more than 15,000 participants across multiple countries. The system is validated for FDA 21 CFR Part 11, is ISO 27001 certified, and supports GDPR and EU Annex 11 requirements alongside ICH GCP guidelines. Castor serves sponsors, CROs, and academic medical centers running studies across 171 countries, with a modular structure that layers eConsent and ePRO on top of the core EDC as needed.

5. Medrio

Medrio offers Medrio CDMS/EDC, a cloud-based platform combining electronic data capture with clinical data management functions such as validation, query management, and audit trails. The system supports both online and offline data capture, which suits sites in regions with inconsistent internet connectivity during multi-country infectious disease studies. Study configuration relies on point-and-click tools rather than custom coding, and Medrio states its platform can go live in hours to days using a code-free base and study-copy functionality. The company reports supporting more than 375 regulatory approvals across MedTech, biotechnology, pharmaceutical, and CRO customers, with 20-plus years of clinical use behind the platform. Medrio is compliant with GCP, 21 CFR Part 11, GDPR, and HIPAA, and is positioned for small and mid-sized study teams that want enterprise-grade data management without enterprise-level complexity.

6. Oracle

Oracle offers Clinical One Data Collection, a platform that goes beyond traditional electronic data capture by harmonizing data from case report forms, electronic health records, wearables, and lab systems in one place. The platform includes integrated randomization and trial supply management, letting sites randomize, dispense drug, and capture patient data within a single system rather than reconciling several vendors. Oracle has added safety integration using the ICH E2B(R3) standard, enabling sites to report serious adverse events directly to sponsors through Clinical One instead of a separate workflow. Oracle states that studies can be built in weeks rather than months, with mid-study changes deployed in real time and no lengthy migration process. Clinical One serves large pharmaceutical and biotech sponsors across all trial phases, with its strongest customer concentration in North America.

What to look for in EDC solutions for vaccine and infectious disease trials

Rapid multi-site scale-up capability

Vaccine and infectious disease trials often need to onboard sites in waves as an outbreak evolves or a recruitment window narrows, rather than launching once and staying static. A platform requiring a fresh validation cycle for every new site cannot keep pace with that curve.

Best-in-class platforms rely on reusable eCRF templates and no-code design, so a new site's forms and edit checks can be stood up in days, not weeks. Look for go-live times measured in single-digit weeks.

A platform that cannot scale site count mid-study forces sponsors to either extend the enrollment window or cap the number of sites, both of which limit statistical power.

Integrated safety and reactogenicity data flow

Vaccine trials generate a high volume of solicited and unsolicited adverse event data, often through daily diaries during the days immediately following each dose. How that data reaches the study team matters as much as how it is collected.

Best-in-class systems sync diary data from Viedoc's ePRO software or an equivalent module directly into the EDC database, then route serious adverse events into a safety workflow using a standard format such as ICH E2B(R3), with no manual reconciliation step in between.

A platform that requires manual reconciliation between diary and EDC data introduces exactly the kind of transcription lag that can obscure an early safety signal.

Randomization and blinding integrity

Most vaccine efficacy trials are randomized, placebo-controlled, and blinded, so a randomization error is not simply a data quality issue but a trial validity issue. The system handling allocation must be as rigorously controlled as the case report form itself.

Best-in-class platforms handle static and dynamic randomization natively, restrict unblinding to defined roles, and log every unblinding event in the same audit trail as the rest of the study data.

Multi-country compliance and data residency posture

Infectious disease trials frequently span dozens of countries at once, each carrying its own data protection expectations and Good Clinical Practice requirements. Waiting to confirm compliance coverage country by country slows exactly the regions where enrollment often moves fastest.

Best-in-class platforms carry FDA 21 CFR Part 11, GDPR, EU Annex 11, and ICH GCP compliance as standard, with broad language support built in rather than added per study on request.

Support responsiveness during active enrollment

Infectious disease trials often run against a clock set by disease incidence rather than internal milestones, so a site issue in one time zone can stall enrollment elsewhere.

Best-in-class vendors offer 24/7 support with direct escalation to engineers, not a ticket queue with a standard response window measured in days.

How to choose the right EDC solution for vaccine and infectious disease trials

Step 1: Define your site activation timeline

Define how many sites need to be live at trial start versus how many will onboard in later waves as enrollment expands. This determines whether you need a platform built for rolling site activation or one built around a single, planned go-live.

Step 2: Assess your safety and diary data architecture

Assess whether your protocol calls for daily reactogenicity diaries, spontaneous adverse event reporting, or both, and confirm the platform routes each data type into one audit trail rather than two systems your team has to reconcile by hand.

Step 3: Evaluate your randomization complexity

Evaluate whether your design needs simple randomization or a more complex adaptive or stratified scheme, since not every platform handles dynamic randomization natively without an added vendor or module.

Step 4: Scrutinize the compliance posture for every country in scope

Scrutinize whether the platform's compliance certifications and language support already cover every country named in your protocol, rather than requiring a custom build for jurisdictions added mid-study.

Step 5: Choose a platform your team can operate independently

Choose a platform your data management team can configure and amend without waiting on a vendor programmer for every change, since that independence protects your timeline once enrollment is underway. Viedoc's no-code Designer is built for this kind of self-sufficiency, and you can book a demo to see how a vaccine or infectious disease study build would run in practice.

Frequently asked questions

What is the best EDC platform for vaccine and infectious disease clinical trials?

Viedoc's EDC platform is the strongest fit for vaccine and infectious disease trials that need to onboard sites quickly, capture reactogenicity diaries alongside standard case report form data, and stay compliant across many countries at once, backed by a 100% FDA inspection pass rate across more than 78,000 completed studies. Medidata remains the default choice for large pharmaceutical sponsors running complex, multi-year Phase III programs where deep ecosystem integration matters more than build speed. Castor EDC is a credible alternative for lower-complexity infectious disease studies that value fast, self-service deployment.

What should I look for when choosing an EDC platform for vaccine trials?

Look for a platform that can onboard new sites quickly without a lengthy validation cycle, since vaccine trials often scale up mid-enrollment as case counts or regulatory timelines shift. Integrated ePRO capture for reactogenicity diaries matters as much as core case report form functionality, since most of the safety signal in a vaccine trial surfaces in the days immediately following each dose. Confirm the platform supports the specific randomization design your protocol calls for, and check that its compliance certifications already cover every country where you plan to enroll.

How long does it take to build and deploy an EDC database for a vaccine or infectious disease trial?

Build timelines vary widely by study complexity and vendor. Self-service teams using Viedoc's no-code Designer can launch a simple database in as little as one day, while a typical professional-services build completes in 8 to 12 weeks. Enterprise platforms built primarily for large Phase III programs, including Medidata's roughly 90-day standard build cycle, tend to run longer, which can matter when an infectious disease trial is racing against a shifting incidence curve.

How does ePRO support adverse event and symptom tracking in vaccine studies?

ePRO software lets trial participants log solicited symptoms, such as injection site reactions or fever, directly from their own device on a fixed schedule after each dose. That data syncs into the EDC database in real time, so study teams see reactogenicity trends as they emerge rather than after a site visit or paper diary is transcribed. The same channel typically captures unsolicited adverse events, which are then routed into the safety review workflow according to the study's adverse event reporting plan.

What compliance certifications matter most for multi-country vaccine trials?

Look for FDA 21 CFR Part 11 compliance for electronic records and signatures, GDPR and EU Annex 11 coverage for European sites, and ICH GCP alignment as a baseline across every region. ISO 27001 and SOC 2 certification indicate the vendor's information security practices have been independently audited, which matters when trial data crosses as many borders as an infectious disease study typically does. HIPAA attestation is relevant for any US sites handling protected health information, and Japan PMDA ERES compliance matters specifically for studies enrolling in Japan.

Can EDC platforms handle rapid multi-site scale-up during an active outbreak response?

The platforms best suited to rapid scale-up are the ones built around no-code, template-driven study design rather than custom programming for every new site. A reusable eCRF library lets a study team stand up a new site's forms and edit checks in days rather than negotiating a fresh build with a vendor programmer each time. Platforms that need heavier professional-services involvement for every site addition, by contrast, tend to struggle to keep pace once a trial scales beyond its original site count.

Making the right EDC choice for vaccine and infectious disease trials

The platforms reviewed here span a wide range of approaches, from enterprise systems built for large, multi-year Phase III programs to modular, self-service platforms for faster-moving studies. The global eClinical software market is estimated at roughly $11.6 billion in 2025, growing at close to 14% annually through 2030. Every vendor here supports core electronic data capture, but they differ sharply in how much site activation speed, safety integration, and multi-country compliance come built in versus added on.

Match your choice to your actual constraints. A large sponsor running one major Phase III program may value deep ecosystem integration over build speed, while a CRO managing several concurrent, multi-country infectious disease studies typically needs faster site onboarding. Teams in the US often weight speed and total cost of ownership most heavily, while EU and APAC teams tend to prioritize compliance credentials and vendor stability.

Switching EDC vendors mid-portfolio carries a real validation burden, so the platform chosen for an early trial in a vaccine program often ends up carrying the whole program forward.

Why Viedoc is the best EDC choice for vaccine and infectious disease trials

If you're running a vaccine or infectious disease trial that needs to scale from a handful of sites to dozens within one enrollment window, Viedoc's EDC platform is built for exactly that kind of pressure. More than 8,000 global studies have run on the platform, and every one has passed FDA inspection, a record that holds up under the scrutiny placebo-controlled vaccine trials typically face.

Viedoc's no-code Designer means your own data managers can configure new sites and amend protocols without waiting on a vendor programmer, and built-in ePRO capture keeps reactogenicity diaries syncing directly into the same database as your case report forms. Unlimited user seats and transparent, study-based licensing mean your costs stay predictable even as the trial grows.

The platform is ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, and backed by 24/7 support with direct escalation to engineers rather than a ticket queue. Viedoc has been running clinical trial data management since 2003.

If your next study needs a platform that can move as fast as your enrollment timeline demands, book a demo or request a proposal and we'll walk through how a study build would run against your specific site and country plan.